2026-11-05 Capital
AZN Reportedly Made ~$10B Offer for Rhythm Pharmaceuticals WSJ reports AZN offered $124/share last month to expand rare disease portfolio
D1 -1.1% · since +0.0%
2026-10-30 Earnings Bull
AZN Reports Q3 and 9M 2026 Results with Revenue and Profit Growth Q3 core EPS beat; oncology sales up 17%; restructuring plan launched
D1 +7.0% · +5d -0.1%
2026-10-30 Earnings
Earnings report 前9个月总营收增长7%，核心每股收益增长14%；剔除Farxiga和Brilinta后总营收增长12%。
D1 +7.0% · +5d -0.1%
2026-10-30 Company
AZN Launches Restructuring Plan Targeting $1.5B Annual Savings Up to $2B one-time costs over 3 years; savings to be reinvested in pipeline
D1 +7.0% · +5d -0.1%
2026-10-26 Product Bull
AZN sonesitatug vedotin cuts death risk by 42% in gastric cancer trial CLARITY-Gastric01 shows significant survival benefit in CLDN18.2-positive advanced gastric cancer
D1 +0.3% · +5d +8.4%
2026-10-26 Product Bull
AZN Readies Filing of First Targeted Cancer Drug Portfolio WSJ reports regulatory filing ahead, cementing oncology position
D1 +0.3% · +5d +8.4%
2026-10-26 Product Bull
AZN TAGRISSO+savolitinib Phase III shows significant survival benefit in lung cancer SAFFRON trial shows 45% reduction in disease progression or death risk and 32% in death risk
D1 +0.3% · +5d +8.4%
2026-10-25 Product Bull
AZN Perioperative Imfinzi plus EV Cuts Recurrence and Death Risk in MIBC Phase III VOLGA trial shows 49% reduction in recurrence risk and 42% in death risk, offering new option for bladder cancer.
D1 +0.3% · +5d +8.4%
2026-10-22 Product Bull
FDA Grants Accelerated Approval to AZN's Ultomiris for IgA Nephropathy Ultomiris receives accelerated FDA approval for IgA nephropathy, its fifth US indication
D1 +2.4% · +5d +1.1%
2026-10-20 Product Bull
AZN/Amgen Tezspire Hits 69% Remission in Phase 3 EoE Trial New indication data supports expansion, commercial payoff unproven
D1 +3.0% · +5d +0.7%
2026-10-15 Capital
B. Riley Wealth Advisors Increases AZN Stake by 101.2% Institutional investor significantly raised holdings in Q3, indicating capital interest
D1 +2.9% · +5d +3.5%
2026-10-12 → 10-15 Product
RBC Keeps Outperform on AZN Ahead of AVANZAR Lung Cancer Trial Data RBC expects quiet Q3, focuses on Friday trial readout
D1 -0.5% · +5d +3.5%
› 2 waves of this story2026-10-12 Phase III data for efzimfotase alfa in HPP shows gains despite missing primary endpoint; Citi maintains buy with peak sales potential2026-10-15 RBC expects quiet Q3, focuses on Friday trial readout2026-10-07 Analyst Bull
Jefferies Maintains Buy on AZN, PT 17,500p Analyst bullish pre-Q3, sees 46% upside
D1 +1.0% · +5d +1.2%
2026-10-06 Company
AZN invests $1B to expand Massachusetts R&D hub Opens new global strategic R&D center in Cambridge; plans to grow local workforce by over 50%
D1 +1.3% · +5d -1.8%
2026-09-29 → 10-05 Capital
AZN deepens Summit tie-up; CEO sees drug powering next-gen cancer combos CEO tells CNBC Summit's lead drug could be future of cancer care; follows earlier Phase III start
D1 -1.2% · +5d -3.4%
› 3 waves of this story2026-09-29 Investment accelerates ivonescimab-ADC combo; backed by UBS and Jefferies2026-10-02 Clinical collaboration with Daiichi Sankyo and Summit to test Datroway plus ivonescimab across tumor types, advancing oncology pipeline2026-10-05 CEO tells CNBC Summit's lead drug could be future of cancer care; follows earlier Phase III start2026-09-29 Regulation
AZN files US FDA application for lung cancer combo ORPATHYS plus TAGRISSO for MET-driven EGFR-mutated lung cancer
D1 -1.2% · +5d -3.4%
2026-09-25 Regulation Bull
AZN Perioperative Bladder Cancer Regimen Granted FDA Priority Review IMFINZI plus EV for muscle-invasive bladder cancer, expanding oncology pipeline
D1 +1.2% · +5d -5.8%
2026-09-23 Product Bull
AZN's Trixeo Wins EU Approval for Asthma Adds indication backed by phase III lung function data
D1 -3.0% · +5d -1.1%
2026-09-21 Regulation Bull
AZN's Klygefa Gets CHMP Positive Opinion for gMG in EU EU CHMP backs AChR-positive gMG, phase III data support convenient once-weekly dosing
D1 +1.2% · +5d -1.2%
2026-09-18 Regulation
FDA Grants Priority Review to AZN's Rare Bone Disease Drug Expands HPP treatment opportunity with less frequent dosing
D1 +0.0% · +5d +0.3%
2026-09-17 Product Bull
AZN's Enhertu Approved for NHS Use in England Expands UK access after Scotland availability, boosting sales potential
D1 +2.0% · +5d -1.0%
2026-09-16 Analyst Bull
J.P. Morgan Reiterates Overweight; Six Phase III Readouts in 2027 in Focus J.P. Morgan reiterates Overweight, citing six Phase III readouts due in 2027
D1 +0.6% · +5d +0.3%
2026-09-15 Analyst Bear
Zacks Adds AZN to Strong Sell List; EPS Estimates Cut 9.1% Zacks adds AZN to Strong Sell list due to 9.1% downward earnings revision
D1 -1.2% · +5d +4.0%
2026-09-15 Product Bear
AZN's Etcamah Fails Phase III in Frontline Breast Cancer SERENA-4 missed PFS primary endpoint; consensus EPS cut 8.49% in 30 days
D1 -1.2% · +5d +4.0%
› 2 waves of this story2026-09-15 SERENA-4 missed PFS endpoint, contrasting with prior approval in advanced setting2026-09-15 SERENA-4 missed PFS primary endpoint; consensus EPS cut 8.49% in 30 days2026-09-08 → 09-09 Product Bull
AZN COPD Data Back Citi's $7B Peak Sales Case Citi backs upside case of at least $7B peak sales, roughly twice consensus, after phase III data
D1 -1.6% · +5d +1.1%
› 2 waves of this story2026-09-08 Two Phase III wins across broad population; raised peak sales forecast supports $80B 2030 revenue goal2026-09-09 Citi backs upside case of at least $7B peak sales, roughly twice consensus, after phase III data2026-09-07 Product Bull
AZN's Etcamah gets FDA accelerated approval; combo cuts progression in breast cancer FDA accelerated approval for camizestrant with CDK4/6 inhibitors in HR+/HER2- advanced breast cancer; reduced progression
D1 -1.6% · +5d +1.1%
› 2 waves of this story2026-09-07 FDA accelerated approval with 56% risk reduction; Citi sees sentiment boost2026-09-07 FDA accelerated approval for camizestrant with CDK4/6 inhibitors in HR+/HER2- advanced breast cancer; reduced progression2026-09-01 → 09-02 Product Bull
AZN Tagrisso Combo Meets PFS Endpoint in 1L NSCLC Phase III Zacks reports positive SANOVO results; Tagrisso plus Orpathys significantly improved PFS
D1 +0.2% · +5d -3.4%
› 3 waves of this story2026-09-01 AZN reports positive Ph3 data for first-line lung cancer combo, bolstering oncology pipeline2026-09-02 SANOVO study shows Tagrisso+Orpathys significantly improves PFS in 1L EGFR-mutated NSCLC2026-09-02 Zacks reports positive SANOVO results; Tagrisso plus Orpathys significantly improved PFS2026-08-27 Product Bull
Tezspire meets all primary, secondary endpoints in Phase III EoE trial Asthma drug hits all endpoints in eosinophilic esophagitis trial, supporting label expansion
D1 -1.1% · +5d +0.2%
